Zobrazeno 11 - 20
of 61
pro vyhledávání: '"Daiki Kayano"'
Autor:
Norihito Akatani, Hiroshi Wakabayashi, Daiki Kayano, Anri Inaki, Aki Takata, Tomo Hiromasa, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Hiroshi Mori, Shintaro Saito, Kenichi Nakajima, Seigo Kinuya
Publikováno v:
Endocrine journal.
Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis remains unexplored in Japan. This study aimed to investigate the long-term survival and prognostic factors of radioiodine therapy (RIT) in a University Hospit
Autor:
Anri Inaki, Tohru Shiga, Yoshito Tsushima, Megumi Jinguji, Hiroshi Wakabayashi, Daiki Kayano, Norihito Akatani, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Tomo Hiromasa, Hiroshi Mori, Kenji Hirata, Shiro Watanabe, Tetsuya Higuchi, Hiroyasu Tomonaga, Seigo Kinuya
Publikováno v:
Annals of Nuclear Medicine. 36:267-278
Objective In this phase II study, we aimed to investigate the efficacy and safety of single-dose [131I]meta-iodobenzylguanidine (131I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL). Patients and methods This study
Autor:
Seigo Kinuya, Hiroshi Wakabayashi, Hiroshi Mori, Tomo Hiromasa, Shintaro Saito, Anri Inaki, Yuji Kunita, Takafumi Yamase, Satoru Watanabe, Norihito Akatani, Daiki Kayano
Publikováno v:
Annals of Nuclear Medicine. 36:61-69
OBJECTIVE Given the rarity of refractory pheochromocytoma and paraganglioma (PPGL), outcomes and prognostic factors after 131I-metaiodobenzylguanidine (131I-mIBG) treatment still remain unclear. Therefore, this study evaluated whether baseline charac
Publikováno v:
Nuklearmedizin. Nuclear medicine. 61(3)
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted the
Publikováno v:
Annals of Nuclear Medicine. 35:649-661
To evaluate the detecting capability between planar imaging (PI) and PI combined with single-photon emission computed tomography/computed tomography (PICWS), including 123I- and 131I-labeled metaiodobenzylguanidine (mIBG) and to compare the detecting
Autor:
Norihito Akatani, Hiroshi Wakabayashi, Daiki Kayano, Anri Inaki, Aki Takata, Tomo Hiromasa, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Hiroshi Mori, Shintaro Saito, Kenichi Nakajima, Seigo Kinuya
Publikováno v:
Endocrine Journal; 2023, Vol. 70 Issue 3, p315-322, 8p
Autor:
Hiroshi Mori, Rie Kuroda, Raita Araki, Seigo Kinuya, Taizo Wada, Anri Inaki, Takafumi Yamase, Satoru Watanabe, Toshihiro Fujiki, Norihito Akatani, Shintaro Saito, Ryosei Nishimura, Hiroshi Wakabayashi, Yuji Kunita, Yasuhiro Ikawa, Tomo Hiromasa, Daiki Kayano
Publikováno v:
Annals of Nuclear Medicine. 34:840-846
Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy
Publikováno v:
Annals of Nuclear Medicine. 34:441-447
131I-meta-iodo-benzyl-guanidine (131I-MIBG) therapy has been used in children with high-risk neuroblastoma, who, in Japan, are cared for by trained nurses. To determine the safety of occupational radiation exposure in nurses, we retrospectively exami
Autor:
Tomo, Hiromasa, Hiroshi, Wakabayashi, Daiki, Kayano, Anri, Inaki, Satoru, Watanabe, Hiroshi, Mori, Norihito, Akatani, Takafumi, Yamase, Yuji, Kunita, Shintaro, Saito, Seigo, Kinuya
Publikováno v:
Annals of nuclear medicine. 36(1)
Given the rarity of refractory pheochromocytoma and paraganglioma (PPGL), outcomes and prognostic factors afterAll patients [n = 59 (male/female = 35/24), median age; 49.3 years] with refractory PPGL who receivedThroughout the follow-up period, 18 pa
Publikováno v:
Kaku igaku. The Japanese journal of nuclear medicine. 58(1)